Adipositas-Play BioAge Labs: Horror-News from Novo-Nordisk-Wettbewerber

With great ambitions, it was in September that the company Biotech-Gesellschaft BioAge Labs and the stock exchange launched. Service providers offer extensive consultancy in the field of adipose disease research, grossing $200 million on a single listing. Doch auf die Euphorie folgte am Nikolaustag die Ernüchterung.

I am working with BioAge Labs for the phase 2 clinical study “STRIDES” for the support of the product Azelaprag in combination with the GLP-1 preparations of tirzepatide (in Eli Lilly’s Zepbound and Mounjaro) to exercise management. bekannt. The Gesellschaft is responsible for research into network resources within the framework of a project, the Azelaprag is carried out.

Data generated by BioAge Labs will not be taken into account and will be available for Apelin receptors in the first quarter of 2025 “updated plan”. The substance Azelaprag is used orally and ahmt the activity of Apelin peptides every time. The product is absorbed by insulin sensitivity and produces glucose.

Durch den Studiennabbruch wachsen die Zweifel, ob die Substanz Azelaprag überhaupt eines Tages zur Behandlung von Fettleibigkeit in Richtung Zulassung geführt werden kann. Hinter der Leitsubstanz dünnt sich die Pipeline von BioAge Labs merklich aus. There is a clear NLRP3 inhibitor for their entry into the clinical study.